sermorelin-ipamorelin: Frequently asked questions

Increase the dose to the next tier (e.g., from 200/200mcg to 300/250mcg) and retest IGF-1 at week 12. Non-responders at starting doses often respond at mid-range dosing. The University of Michigan trial found that 18% of participants required dose escalation to achieve target IGF-1 elevation above 30ng/mL. If IGF-1 remains unchanged at 500/300mcg dosing, verify reconstitution and storage procedures first (peptides stored above 8°C lose potency irreversibly), then assess baseline pituitary function with an endocrinologist. Primary pituitary insufficiency will not respond to secretagogue stimulation.

Resume the protocol at your current dose without attempting to 'catch up' by doubling doses. Missing doses temporarily lowers IGF-1, but the decline is gradual. Serum IGF-1 has a half-life of approximately 12–15 hours, so a 72-hour gap reduces levels by roughly 40%, not to zero. The physiological GH pulse resets within 48 hours of resuming nightly injections. Dose-doubling creates supraphysiological GH spikes that increase insulin resistance and water retention risk without proportional benefit.

Switch injection sites daily (rotate between abdomen, thighs, upper arms) and ensure the peptide solution has reached room temperature before injecting. Cold injections increase local irritation. If welts persist, the issue is typically benzyl alcohol sensitivity in the bacteriostatic water. Switching to preservative-free sterile water for reconstitution eliminates this reaction but shortens the solution's shelf life to 7 days refrigerated. Persistent reactions at multiple sites suggest peptide contamination or impurity. Third-party purity testing via HPLC should confirm >98% purity for research-grade compounds.

Verify peptide storage and reconstitution first. A temperature excursion above 8°C for more than 2 hours denatures both sermorelin and ipamorelin irreversibly, and many "non-responders" are actually using degraded product. Request a replacement vial stored under verified cold-chain conditions and retest IGF-1 at 4 weeks. If levels remain unchanged with confirmed viable peptides, the issue is likely inadequate dosing for your body mass or a blunted GH response due to elevated cortisol, chronic sleep restriction (less than 6 hours nightly), or insulin resistance. Research published in Hormone Research found that individuals with fasting insulin above 12 μIU/mL showed 40% lower GH response to secretagogue stimulation compared to insulin-sensitive controls. Addressing metabolic dysfunction through dietary intervention (targeting fasting insulin below 8 μIU/mL) restores normal GH axis responsiveness in most cases. Some protocols increase the sermorelin dose to 400–500 mcg while maintaining ipamorelin at 200 mcg to overcome partial resistance, but this should occur under medical supervision with serial IGF-1 monitoring.

No. Administer your regular dose on the next scheduled evening and continue the protocol without compensating for the missed dose. Doubling the dose creates supraphysiological GH levels that trigger negative feedback through elevated IGF-1 and somatostatin release, which suppresses your body's natural GH production for 36–48 hours after the excess dose. Missing a single injection has minimal impact on cumulative IGF-1 levels (the half-life of IGF-1 is approximately 12–15 hours, so one missed pulse doesn't crash your weekly average), but doubling doses disrupts the pulsatile rhythm the protocol is designed to preserve. If you miss more than two consecutive doses per week, the benefits diminish. Consistency matters more than occasional compensation.

Rotate injection sites across at least four abdominal quadrants (alternating lower-left, lower-right, upper-left, upper-right) and ensure you're injecting into subcutaneous adipose tissue rather than intramuscular or intradermal layers. Subcutaneous injections should use a 29–31 gauge insulin syringe inserted at a 45-degree angle with a pinched skin fold; if you're hitting muscle (indicated by injection pain or faster absorption with shorter duration of effect), you're inserting too deeply. Injection site reactions. Redness, itching, or raised welts lasting more than 4 hours. Are most often caused by benzyl alcohol sensitivity in bacteriostatic water; switching to preservative-free sterile water for reconstitution (with strict single-use, discard-after-draw protocol) resolves this in approximately 80% of cases. Persistent reactions suggest peptide impurity or allergic response to the amino acid sequence itself, which requires discontinuation and prescriber consultation.

No. Sermorelin and ipamorelin don't suppress endogenous GH production the way exogenous growth hormone does. These are secretagogues (compounds that stimulate your own pituitary to release GH), not replacement hormones, so there's no negative feedback loop suppressing natural secretion. When you stop the stack, your GH levels return to baseline within 48–72 hours as the peptides clear (both have plasma half-lives under 30 minutes, though their stimulatory effect on pulsatile release lasts 2–4 hours per dose). IGF-1 levels decline more gradually due to IGF-1's longer half-life, normalizing over 10–14 days. Some clinicians recommend a taper protocol (reducing dose by 50% for one week before stopping entirely) to smooth the IGF-1 descent, but there's no physiological rebound or withdrawal effect. If your baseline GH production was suboptimal before starting the protocol, returning to baseline means returning to that suboptimal state. The peptides don't create lasting improvement in endogenous secretion, they amplify it while active.